NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus.
Neuralstem president and CEO Richard Garr said that the commencement of the first trial in the small molecule platform represents a major milestone for Neuralstem.
"In addition to our ongoing programs in cell therapeutics, we are now advancing a new class of orally administered drugs that recruit endogenous neural stem cells," Garr said.